Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand  Is a corresponding author
  1. University of Oklahoma Health Sciences Center, United States
  2. Technical University of Denmark, Denmark
  3. University at Buffalo School of Medicine, United States
  4. La Jolla Institute for Allergy and Immunology, United States
  5. University of Chicago, United States
  6. University of Oklahoma Health Science Center, United States

Abstract

HLA class I presentation of pathogen-derived peptide ligands is essential for CD8+ T-cell recognition of Toxoplasma gondii infected cells. Currently, little data exist pertaining to peptides that are presented after T. gondii infection. Herein we purify HLA-A*02:01 complexes from T. gondii infected cells and characterize the peptide ligands using LCMS. We identify 195 T. gondii encoded ligands originating from both secreted and cytoplasmic proteins. Surprisingly, T. gondii ligands are significantly longer than uninfected host ligands, and these longer pathogen-derived peptides maintain a canonical N-terminal binding core yet exhibit a C-terminal extension of 1-30 amino acids. Structural analysis demonstrates that binding of extended peptides opens the HLA class I F' pocket, allowing the C-terminal extension to protrude through one end of the binding groove. In summary, we demonstrate that unrealized structural flexibility makes MHC class I receptive to parasite-derived ligands that exhibit unique C-terminal peptide extensions.

Article and author information

Author details

  1. Curtis McMurtrey

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Trolle

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  3. Tiffany Sansom

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Soumya G Remesh

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Thomas Kaever

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Wilfried Bardet

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Kenneth Jackson

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Morten Nielsen

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  9. Rima McLeod

    University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Dirk M Zajonc

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ira J Blader

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Bjoern Peters

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alessandro Sette

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. William Hildebrand

    Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, United States
    For correspondence
    william-hildebrand@ouhsc.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, McMurtrey et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,331
    views
  • 501
    downloads
  • 69
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand
(2016)
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove
eLife 5:e12556.
https://doi.org/10.7554/eLife.12556

Share this article

https://doi.org/10.7554/eLife.12556

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Malika Hale, Kennidy K Takehara ... Marion Pepper
    Research Article

    Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.

    1. Immunology and Inflammation
    Zhiyan Wang, Nore Ojogun ... Mingfang Lu
    Research Article

    The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.